Aposture Surgical Corp discloses $150,000 SAFE offering in SEC Form D
The Philadelphia biotech, formerly BioSpine Corp, reported $87,000 raised toward the target as of a first sale date of August 7, 2026.
Aposture Surgical Corp filed a Form D with the Securities and Exchange Commission disclosing a new exempt securities offering. The filer's CIK is 0002148299, and its previous name was BioSpine Corp. The company is a Delaware corporation incorporated within the last five years, in 2024.1
Aposture Surgical Corp is based at 1635 Market Street, Suite 1525, in Philadelphia, Pennsylvania.1 The filing lists John Hail Chung as an executive officer and director at the same Philadelphia address, and Kyung Woo Park as a director based in Seoul, Republic of Korea.1
The company classified its industry as biotechnology within the health care category.1 It reported no revenues as of the filing.1
The offering is claimed under the Rule 506(b) exemption.1 The filing is a new notice, with a date of first sale listed as August 7, 2026.1 The company does not intend the offering to last more than one year.1
The security type offered is described as "Other," specifically a Simple Agreement for Future Equity (SAFE).1 The offering is not being made in connection with a business combination transaction.1
The minimum investment accepted from any outside investor is $1,000.1 The filing reports no sales compensation recipients, broker-dealers, or associated CRD numbers.1
The total offering amount is $150,000, with $87,000 sold and $63,000 remaining to be sold.1 Three investors have already invested in the offering.1 The company reported $0 in sales commissions and $0 in finders' fees.1 Proceeds directed to executive officers, directors, or promoters were also reported as $0.1
The notice was signed by John H. Chung, President of Aposture Surgical Corp, on August 13, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.